Freya Biosciences is at the forefront of developing innovative microbial immunotherapies aimed at addressing significant reproductive health challenges faced by women. The company focuses on the chronic inflammation and immune dysregulation associated with various reproductive disorders, such as infertility, endometriosis, and preterm birth. By leveraging a data-driven approach, Freya utilizes advanced techniques like quantitative and whole genome sequencing, along with extensive biomarker analysis, to better understand the underlying immune mechanisms and microbiome dynamics that contribute to these conditions. Their lead candidate, FB101, is currently undergoing clinical trials to evaluate its efficacy in treating women with dysbiotic vaginal microbiota, which has been linked to poor IVF outcomes.

In addition to their primary focus on infertility and related conditions, Freya is also exploring therapeutic opportunities for other diseases driven by local immune dysregulation. The company has established partnerships with leading IVF centers, such as Boston IVF, to conduct large-scale studies that investigate the relationship between vaginal microbiota and reproductive health outcomes. This collaborative effort aims to fill the existing gaps in therapeutic options for women, particularly those experiencing dysbiosis during IVF or natural conception attempts. Freya's commitment to advancing women's health through cutting-edge science positions it as a key player in the field of reproductive health innovation.

Denmark

Freya™ is a clinical-stage company taking an innovative approach to women’s health, with microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of reproductive system diseases uniquely afflicting women.

Freya Biosciences

Company Details